IBDEI1JT ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24752,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,24752,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,24752,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,24753,0)
 ;;=D61.9^^107^1211^28
 ;;^UTILITY(U,$J,358.3,24753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24753,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,24753,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,24753,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,24754,0)
 ;;=D56.1^^107^1211^30
 ;;^UTILITY(U,$J,358.3,24754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24754,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,24754,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,24754,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,24755,0)
 ;;=C83.79^^107^1211^32
 ;;^UTILITY(U,$J,358.3,24755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24755,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,24755,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,24755,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,24756,0)
 ;;=C83.70^^107^1211^33
 ;;^UTILITY(U,$J,358.3,24756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24756,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,24756,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,24756,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,24757,0)
 ;;=D09.0^^107^1211^40
 ;;^UTILITY(U,$J,358.3,24757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24757,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,24757,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,24757,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,24758,0)
 ;;=D06.9^^107^1211^41
 ;;^UTILITY(U,$J,358.3,24758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24758,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,24758,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,24758,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,24759,0)
 ;;=D06.0^^107^1211^43
 ;;^UTILITY(U,$J,358.3,24759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24759,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,24759,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,24759,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,24760,0)
 ;;=D06.1^^107^1211^44
 ;;^UTILITY(U,$J,358.3,24760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24760,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,24760,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,24760,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,24761,0)
 ;;=D06.7^^107^1211^42
 ;;^UTILITY(U,$J,358.3,24761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24761,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,24761,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,24761,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,24762,0)
 ;;=D04.9^^107^1211^45
 ;;^UTILITY(U,$J,358.3,24762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24762,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,24762,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,24762,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,24763,0)
 ;;=C91.11^^107^1211^48
 ;;^UTILITY(U,$J,358.3,24763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24763,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,24763,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,24763,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,24764,0)
 ;;=C91.10^^107^1211^49
 ;;^UTILITY(U,$J,358.3,24764,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24764,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
